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A new solid-phase enzyme-linked assay for riboflavin (vitamin B2) is described. The assay is 
based on the competition between analyte vitamin molecules and a glucose-6-phosphate dehy- 
drogenase-3carboxymethylriboflavin conjugate for a limited number of riboflavin-binding 
protein sites immobilized on Sepharose particles. Significant improvements in conjugate cata- 
lytic activity and thus detectability are achieved by optimizing the reaction conditions used to 
covalently link 3-carboxymethylribofavin to the enzyme. Optimization experiments include 
studying the effects of reaction pH and organic solvent composition. Final assay detection limits 
and the sensitivity of the dose-response curves are dependent on the ratio of conjugate to 
binding protein sites utilized in an equilibrium assay protocol. Selectivity of the method corre- 
lates well with that predicted based on the known association constants of riboflavin-binding 
protein with flavin analogs. The assay is shown to offer adequate detection limits and selectivity 
for direct measurement of riboflavin in urine, infant formula, and vitamin capsules. Q 1988 
Academic Press, Inc. 
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Enzyme-linked competitive binding assays 
are now routinely used in place of radioim- 
munoassay methods to determine a variety 
of biomolecules at trace levels (l-4). While 
selective antibodies are typically employed as 
the binding reagents in such methods, we re- 
cently demonstrated that the use of natural 
binding proteins in place of antibodies can 
offer some unique advantages in both hetero- 
geneous (solid-phase) (S-7) and homoge- 
neous (S-10) assay arrangements. The pur- 
pose of this report is to further examine this 
approach by describing a new assay for ribo- 
flavin (vitamin Bz). 
Several methods already exist for the de- 
termination of riboflavin in biological sam- 
ples. The classical technique involves a mi- 
crobiological assay using bacterial cells 
which require riboflavin for growth ( 11,12). 
Unfortunately, such bioassay procedures are 
quite slow and provide only semiquantitative 
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results. Modern liquid chromatography 
methods may also be used; however, these 
methods require that many samples be de- 
proteinated prior to injection onto the ana- 
lytical column ( 13,14). 
Riboflavin assays based on selective 
binders have also been described. However, 
as with other natural vitamins, efforts to de- 
velop high-affinity antibodies selective for ri- 
boflavin have met with limited success 
(l&16). This lack of adequate immune re- 
sponse requires that a natural binder be uti- 
lized in such assays. Riboflavin-binding pro- 
tein (RBP)3 (17-20) from chicken egg white 
may be used for such purposes (2 l-23). In- 
deed, Tillotson and Bashor have reported a 
fluorescent titration method based on 
quenching of riboflavin fluorescence by RBP 
3 Abbreviations used: RBP, riboflavin-binding pro- 
tein; G6PDH, glucose-Qphosphate dehydrogenase; RF, 
riboflavin; LF, lumiflavin; LC, lumichrome; FMN, fla- 
vin mononucleotide; DMF, N,N-dimethylformamide; 
DCC, N,N’-dicyclohexylcarbodiimide; NHS, N-hy- 
droxysuccinimide; G6P, glucosed-phosphate; DMSO, 
dimethyl sulfoxide. 
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(22). Lotter et al. have described a competi- 
tive binding assay using radiolabeled ribofla- 
vin (23). In each of these methods, the RBP 
was used in soluble form and there is little 
information to date regarding the binding 
ability and selectivity of RBP when cova- 
lently immobilized on a solid support. 
In this paper we describe a new, nonra- 
dioisotope method for the determination of 
riboflavin. The method is based on the com- 
petition of riboflavin with an enzyme-ribo- 
flavin conjugate for a limited number of 
RBP binding sites immobilized on Sepharose 
particles. After equilibration and separation, 
the amount of enzyme activity bound to the 
particles is inversely proportional to the con- 
centration of riboflavin in the sample. De- 
tectability of the conjugate is improved by 
carefully optimizing the conditions used for 
coupling 3-carboxymethyhiboflavin to the 
enzyme, glucose-6-phosphate dehydroge- 
nase. The final assay is shown to be selective 
and sensitive enough to detect riboflavin di- 
rectly in urine, infant formula, and multivi- 
tamin capsules. 
MATERIALS AND METHODS 
Apparatus 
Enzyme activities were measured with a 
Gilford Stasar III spectrophotometer 
equipped with a vacuum-operated sampling 
system and temperature-controlled cuvette 
(maintained at 30°C throughout the experi- 
ments). This spectrophotometer was con- 
nected to a Syva CP-5000 EMIT Clinical 
Processor for automatically setting the read- 
ing intervals and recording the absorbance 
values. A Perkin-Elmer Lambda Array 3840 
photodiode array UV/VIS spectrophotome- 
ter operated by a Model 7300 professional 
computer was used to record the UV/VIS 
spectra of the enzyme, riboflavin, riboflavin 
analogs, and conjugates. 
Reagents 
Glucose-6-phosphate dehydrogenase 
(G6PDH) from Leuconostoc rnesenteroides, 
apo-RBP from chicken egg white, riboflavin 
(RF), lumiflavin (LF), lumichrome (LC), 
flavin mononucleotide (FMN), and flavin- 
adenine dinucleotide (FAD), as well as 
all other biochemicals, were obtained 
from Sigma Chemical Co. and were of the 
highest purity available. Anhydrous NJ- 
dimethylformamide (DMF) (water content 
< 0.005%) was obtained from Aldrich, while 
ethyl bromoacetate was purchased from 
Eastman Kodak Co. All other chemicals 
were of reagent grade or better. Deionized- 
distilled water was used throughout the 
study. 
Activity measurements of G6PDH and its 
conjugates were performed in 0.050 M 
Tris(hydroxymethyl)aminomethane-hydro- 
chloric acid (Tris-HCl) buffer, pH 7.8, con- 
taining 0.10 M NaCl and 0.01% (w/v) NaN3 
(assay buffer). The dilutions of conjugates, 
standards, and samples were made using this 
assay buffer containing 0.10% (w/v) gelatin 
(Tris-gelatin buffer). 
Preparation of G6PDH-3- 
Carboxymethylriboflavin Conjugates 
Figure 1 summarizes the scheme used to 
prepare G6PDH-riboflavin conjugates. De- 
tails of this scheme are described below. 
Preparation of N-hydroxysuccinimide 
ester of 3-carboxymethylribojlavin. 3-Car- 
boxymethylriboflavin was synthesized ac- 
cording to a published method (24,25). In 
order to prepare the NHS-activated form of 
3-carboxymethylriboflavin, N,N’-dicyclo- 
hexylcarbodiimide (DCC) (0.50 mmol) was 
added to a solution of 3-carboxymethylribo- 
flavin (0.55 mmol) and NHS (0.50 mmol) in 
15 ml of anhydrous DMF at 0°C. The reac- 
tion was allowed to continue for 48 h in the 
dark (to prevent photodegradation of the 
N( 10) side chain of riboflavin) at 4°C with 
stirring. Dicyclohexylurea formed during the 
reaction was removed by filtration. The acti- 
vated product was isolated by evaporating 
DMF at reduced pressure and by washing the 
resulting residue with ethanol. Any remain- 
ing DMF, DCC, or NHS was removed by 
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washing with ethanol, a solvent in which the 
activated ester product is not soluble. The 
activated ester prepared in this manner was 
stable for at least 6 months when stored 
below 0°C. 
Conjugation of enzyme to activated ester. 
The required amount of NHS-activated 3- 
carboxymethyhiboflavin was added to 400 ~1 
of cold coupling buffer (e.g., 0.10 M bis-Tris 
propane, pH 6.5) with vigorous stirring. A 
400~~1 aliquot of the enzyme solution (250 
units/ml, previously dialyzed in coupling 
buffer) was immediately added to the acti- 
vated ester solution and mixed vigorously. 
The conjugation reaction was run for 6 h in 
the dark at 4’C with stirring. The active site 
of the enzyme was protected (6) during the 
conjugation reaction by adding an excess of 
glucose 6-phosphate (G6P) and P-NADH 
(compared to the concentration of enzyme 
present). Finally, the conjugate was dialyzed 
against the assay buffer (Tris-HCl, pH 7.8). 
Each conjugate was characterized by the 
degree of conjugation (average number of li- 
gands per enzyme molecule) and by its resid- 
ual enzymatic activity. The degree of conjuga- 
tion was estimated from calculations involv- 
ing absorbance measurements at two 
absorption maxima of the conjugate (27 I and 
452 nm) (26). The residual enzymatic activity 
was calculated by comparing the activities of a 
conjugated enzyme to that of a solution con- 
taining unconjugated enzyme of the same 
protein concentration. Several G6PDH-3- 
carboxymethylriboflavin conjugates were 
prepared by using different initial ligand/en- 
zyme ratios in the conjugation reaction and 







in Bis-tris propane, pH 6.5 
Activated ester ’ Conjugate 
FIG. 1. Reaction sequence for preparation of G6PDH-3-carboxymethyhiboflavin conjugates. 
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TABLE 1 
















Degree of Percentage Relative affinity 
conjugation residual activity for RBP beads* 
1.8 75.3 1.0 
4.5 69.2 3.8 
7.0 63.0 14.5 
14.1 53.9 34.2 
20.7 50.3 44.4 
26.7 43.8 59.6 
n Refers to molar ratios of NHS-activated 3-carboxymethylriboflavin to G6PDH in the conjugation reaction. 
’ For all conjugates, a fixed amount of protein was incubated with a fixed amount of RBP beads. The resulting 
absorbance changes were divided by percentage residual activity of the corresponding conjugates and normalized 
with respect to conj- 1. 
Enzymatic Activity Determination 
The rate of appearance of NADH, mea- 
sured by the change in absorbance at 340 nm 
per unit time, was used to determine the ac- 
tivity of the G6PDH-riboflavin conjugates. 
The assay involves addition of 100 ~11 of 
P-NAD+ substrate (0.060 M P-NAD+ in assay 
buffer), 100 ~1 of G6P substrate (0.10 M G6P 
in assay buffer), and 100 ~1 of the enzyme 
conjugate solution (in Tris-gelatin buffer) to 
a disposable sample cup containing 700 ~1 of 
assay buffer. After agitation the reaction 
mixture was aspirated into the thermostated 
flow cell of the Gilford spectrophotometer. 
Absorption measurements were taken after a 
30-s delay to allow for temperature equili- 
bration. 
Preparation of RBP Beads and Association 
Study 
Riboflavin-binding beads were prepared 
by covalently attaching OS or 2.5 mg of apo- 
RBP to 400 mg of CNBr-activated Sepharose 
4B beads as suggested by the manufac- 
turer (27). 
The kinetics of binding between the en- 
zyme-riboflavin conjugates and the solid 
phase was studied for each set of RBP beads 
prepared. For these studies, lOO-~1 portions 
of 5.80 X 10e9 M conjugate (conj-5) were in- 
cubated for varying time intervals with a 
fixed amount of RBP beads (30 ~1 for low 
coverage beads and 2.5 ~1 for high coverage 
beads), all in a total volume of 800 ~1 of assay 
buffer. After each incubation period, the 
tubes were centrifuged and the supernatants 
were discarded. The beads were then washed 
three times with 2.0 ml of assay buffer. The 
pellet was finally resuspended in a total vol- 
ume of 1 .O ml containing 100 ~1 of each sub- 
strate solution and incubated for 1 h at room 
temperature. After centrifugation the absor- 
bance of the supernatant was determined. 
Binding Protein Dilution Curves 
In order to determine the binding capacity 
of the RBP beads for the conjugates, varying 
volumes of a 1:25 suspension (volume 
beads/total volume) of RBP beads were in- 
cubated with 100 ~1 of 1.45 X lo-* M conju- 
gate (conj-2, conj-3, and conj-5). The final 
volume of each tube was brought to 800 ~1 
with assay buffer. The reaction mixtures were 
incubated for 2 h, centrifuged and washed, and 
the resulting activity of the beads was mea- 
sured after a l-h incubation as described 
above. 
Preparation of Standard Solutions 
A stock solution of riboflavin was pre- 
pared from riboflavin recrystalized by the 
procedure described elsewhere ( 19). Stock 
solutions of lumiflavin, lumichrome, FMN, 
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and FAD were prepared without further pu- 
rification. A given amount of each flavin was 
dissolved in deionized-distilled water and 
the concentrations of these stock solutions 
were determined spectrophotometrically 
using molar extinction coefficients (ced5 
= 1.25 X lo4 M-’ cm-’ for RF, e441 = 1.28 
X 104M-‘Cm-‘forLF,c356= 1.15X 104M-’ 
cm-’ for LC, c445 = 1.24 X lo4 M-’ cm-’ for 
FMN, and c450 = 1.13 X lo4 M-’ cm-’ for 
FAD) ( 19). Standard solutions of each flavin 
were prepared from dilutions of the corre- 
sponding stock solutions with Tris-gelatin 
buffer, stored in the dark at 4°C and used as 
soon as possible. 
Dose-Response Curves 
Dose-response curves were run in a single 
incubation (equilibrium) mode (28). One- 
hundred-microliter portions of the flavin 
standards were incubated with 100 ~1 of a 
conjugate solution and a given amount of 
RBP beads for 2 h, all in a total volume of 
800 ~1 of assay buffer. The resulting activity 
of the beads was measured after the 3-h in- 
cubation procedure as described above. 
Dose-response curves were prepared by 
plotting absorbance at 340 nm vs logarithm 
of the flavin concentration in the standards. 
Sample Preparations and Riboflavin 
Determinations 
Multivitamin capsules. The contents of 
three capsules of the commercial multivita- 
min preparation were weighed and mixed. A 
quantity of this powdered mixture (approxi- 
mately 30 mg) was weighed and dissolved in 
2000 ml of deionized-distilled water. This 
preparation was then diluted 1:50 or 1: 100 
with Tris-gelatin buffer. 
Urine. Twenty-two random urine samples 
were diluted 1:25 or 1:50 with Tris-gelatin 
buffer. The precipitate, if any, dissolved 
when the sample was diluted. 
Infant formula. Samples of the liquid in- 
fant formula were prepared by diluting 1: 100 
with Tris-gelatin buffer. 
All of these sample preparations were 
stored at 4°C and protected from light. A 
single incubation assay protocol described 
above (in place of standards) was used and 
the unknown concentrations were estimated 
graphically from the calibration curve, which 
was run simultaneously with the riboflavin 
standards (only in the steep portion of the 
dose-response curve). When the concentra- 
tion of the initial dilution of the sample was 
not in the working range of the curve, an 
additional dilution was made. 
RESULTS AND DISCUSSION 
The analytical performance of the pro- 
posed enzyme-linked competitive binding 
assay is primarily dependent upon the associ- 
ation constants of both labeled and unla- 
beled riboflavin with the binder (K and K*, 
respectively). Naturally, K* must be high 
enough so that relatively low concentrations 
of both conjugate and immobilized binder 
(low reagent costs) can be utilized, yet high 
enough so that the catalytic activity of the 
conjugate bound to the solid phase can be 
easily monitored within a reasonably short 
measurement period. It is known that N(3)- 
carboxymethyhiboflavin binds to RBP with 
the highest association constant (7.1 X IO’ 
M-‘) (29) of all the riboflavin analogs con- 
taining a free carboxyl group (required to 
form a stable peptide linkage with a primary 
amino group of the enzyme). It has also been 
reported that, of the riboflavin analogs im- 
mobilized by covalent attachment to the 
solid phase, those attached at position N(3) 
are bound to RBP more tightly than those 
through positions 8, or ZV( 10) (30). There- 
fore, N(3)-carboxymethyhiboflavin attached 
to the enzyme through its free carboxyl 
group was employed to prepare all conju- 
gates used in this study. 
The final assay characteristics are also 
highly dependent upon the detectability and 
degree of ligand substitution in the enzyme- 
ligand conjugate utilized. Consequently, we 
carefully optimized the conditions used for 
coupling 3-carboxymethylriboflavin to 
G6PDH. Traditionally, DMF is used as a 
solvent in the formation of activated esters of 
carboxylated ligands, and this activated mix- 
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ture is added to the conjugation reaction me- 
dium without further treatment (3 1,32). The 
presence of DMF, however, is believed to in- 
hibit the G6PDH irreversibly during the con- 
jugation reaction. Indeed, Bachas and 
Meyerhoff (5,6) found that a modified NHS 
ester method (in which a mixed solvent sys- 
tem (DMSO/DMF) is used rather than DMF 
alone) yields better conjugates. However, 
even this mixed organic solvent was found to 
alter the G6PDH activity substantially, espe- 
cially when highly substituted conjugates 
were prepared (higher initial ligand/enzyme 
ratios in conjugation reaction). Therefore, in 
an effort to completely eliminate the effect of 
organic solvents on the enzyme activity, the 
activated ester of 3carboxymethylriboflavin 
was isolated as described under Materials 
and Methods. Indeed, conjugates prepared 
with the isolated activated ester had better 
residual enzymatic activity compared to 
those prepared in the mixed solvent system 
of DMSO and DMF. For example, using the 
same initial ester/enzyme ratio (800), the 
mixed solvent system yielded a conjugate 
with a degree of conjugation of 5.8 and a 
residual activity of 1.5%, while a conjugate 
prepared with the isolated activated ester had 
a degree of conjugation of 11.1 and a residual 
activity of 32.7%. 
Subsequent experiments revealed that the 
optimum pH for coupling NHS-activated 3- 
carboxymethylriboflavin to G6PDH is 
slightly acidic pH 6.5 rather than the pH 
9.0-9.5 frequently reported in the literature 
for ligand-enzyme conjugation reactions in- 
volving NHS methods (31,32). bis-Tris pro- 
pane was utilized to prepare several different 
conjugation reaction buffers since it provides 
a wide pH range (pH 6.3 to 9.5) and has no 
primary amino group. Bicarbonate buffer 
(pH 9.5) was also utilized for comparison 
purposes. As shown in Fig. 2., using the same 
initial ligand/enzyme ratio, a lower reaction 
pH produced a greater degree of conjugation. 
Similar results were obtained with a succinyl 
cyclic AMP-G6PDH system by Carter and 
Meyerhoff (unpublished work). This pH ef- 
fect may be due to reduced hydrolysis of the 
NHS-activated ester at lower pH (27). It is 
generally believed that the higher the degree 
of conjugation, the less residual enzymatic 
activity results. Contrary to this assumption, 
however, we found that a conjugate with a 
lower degree of conjugation prepared using a 
higher pH buffer showed less residual activ- 
ity than a conjugate with a higher degree of 
conjugation prepared at low pH (see Fig. 2). 
This strange behavior becomes even more 
dramatic in pH 9.5 bicarbonate buffer. 
Clearly, the reaction pH strongly affects the 
enzyme activity during the conjugation reac- 
tion. 
Under the optimized coupling condition 
utilizing the isolated NHS-activated ester 
and the pH 6.5 bis-Tris propane buffer (Fig. 
l), several G6PDH-3-carboxymethylribofla- 
vin conjugates were prepared using different 
initial ligand/enzyme ratios. Table 1 summa- 
rizes the characteristics of the resulting con- 
jugates. As expected, increasing the initial 
molar ratio of ligand/enzyme resulted in 
greater degrees of conjugation with less resid- 
ual activities. Significant improvements in 
conjugate catalytic activity were achieved, 
especially for highly substituted conjugates. 
For example, even a conjugate (conjd) with 
a degree of conjugation of 26.7 possessed a 
residual activity of 43.8%, which was more 
than adequate for use in the proposed assay 
system. It should be noted that, while highly 
substituted and active G6PDH-ligand con- 
jugates have been utilized previously in suc- 
cessful homogeneous competitive binding 
assays (8, IO), the G6PDH-riboflavin conju- 
gates described here were not inhibited to a 
significant degree by excess soluble RBP. 
The association rate constants of soluble 
RBP toward flavin analogs, estimated by the 
quenching of flavin fluorescence, are on the 
order of 10’ to 10’ M-’ s-’ (19). These ex- 
tremely fast association kinetics are not rele- 
vant to the immobilized RBP system. Once 
immobilized on a solid phase support, RBP 
suffers from steric hindrance and can not 
freely move in solution, lowering its overall 
association kinetics. It was expected that an 
increase in the number of immobilized 
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binder molecules per unit surface area would 
further decrease the association reaction rate 
due to increased steric effects, particularly 
when the immobilized protein must bind to 
a bulky enzyme-ligand conjugate. Figure 3 
illustrates this point. For this study, the same 
amount of Sepharose beads (400 mg) was 
used for the immobilization of 0.5 or 2.5 mg 
of RBP, respectively, and a given amount of 
these RBP beads was incubated for varying 
time intervals with a fixed conjugate concen- 
tration. As can be seen, faster equilibrium (in 
1 h) was achieved when less RBP is immobi- 
lized on the beads. Therefore, in all subse- 
quent studies, the particles with low RBP 
coverage were employed with the 2-h incu- 
bation period. 
In order to evaluate the binding capacity 
of the RBP beads for the conjugates, binding 
dilution curves were constructed using the 
same concentration of three different conju- 
gates (conj-2, conj-3, and conj-5). As shown 
in Fig. 4, much more enzyme activity can be 
pulled out of solution when a conjugate with 
a greater degree of ligand substitution is used. 
Such multivalent conjugates can be consid- 
ered as having independent ligand mole- 
cules, each one having the same microscopic 
association constant for the binder (33). 
Therefore, increasing the number of ligands 
attached to the enzyme label will effectively 
increase the association constant between the 
conjugate and immobilized RBP. The effect 
of multivalency was examined with all con- 
jugates prepared and summarized in the last 
column of Table 1. For this study, a fixed 
amount of RBP beads (200 ~1 of 1: 100 sus- 
pension) was incubated with a fixed amount 
of each conjugate (100 ~1 of 1.45 X 1 O-* M). 
The resulting absorbance changes were di- 
vided by percentage residual enzymatic ac- 
tivity of the corresponding conjugates and 
thus normalized to provide relative bound 
activities. The association constant of the 
multivalent conjugate with the binder can be 
defined as K, = nK* (34), where n is the 
effective degree of conjugation. While the re- 
sults obtained here cannot be quantitatively 
compared with the theory because the exper- 
imental method involves washing steps to 
separate enzyme-ligand conjugate bound to 
the solid phase (multiple equilibria), the data 
do exhibit the expected trend for the in- 
creased statistical association constant (KS&J 
8 
8- 
6.!%Bis-) 7.5(Bis-) 8.5(BiS-) 9.5(Bis-) 9.5(Bidar-1 
pH of Coupling Buffer 
FIG. 2. Effect of conjugation reaction pH on the degree of conjugation (Cl) and residual activity (X) of 
G6PDH-3-carboxymethylriboflavin conjugates. The same initial ligand/enzyme ratio (300: 1) was used in 
all conjugation reactions. 
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Incubation Time, min 
FIG. 3. Effect of the amount of immobilized RBP per unit surface area of Sepharose beads on the 
association kinetics of G6PDH-3-carboxymethyhiboflavin with RBP beads. The same amount of Sepha- 
rose beads (400 mg) was used for the immobilization of 0.5 (Cl) or 2.5 mg (X) of RBP, respectively. Data 
points are means of duplicate measurements. 
of the multivalent conjugate (as evidenced by the proposed competitive binding riboflavin 
increasing bound activities for fixed conju- assay, each will exhibit different characteris- 
gate concentrations). While any of the con- tics in terms of assay performance (e.g., de- 










Volume of RBP beads. )rl 
20 24 
FIG. 4. Binding protein dilution curves obtained by incubating varying amounts of RBP beads with 100 
~1 of 1.45 X lOWE M conjugate; (Cl) conj-2; (X) conj-3; (0) conj-5. The x-axis refers to settled volume of RBP 
beads. Means of duplicate measurements are plotted. 
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cause of different effective K* values. For 7.8 X 108/20.7 M-‘, which is less than that for 
this study we arbitrarily chose the conjugate free 3carboxymethyhiboflavin (7.1 X 10’ 
with a degree of conjugation of 20.7 (conj-5) M-l). It is likely that attachment of a bulky 
for all subsequent competitive binding ex- group (enzyme) would, in fact, reduce the 
periments. binding ability of the flavin toward RBP. 
Three dose-response curves were con- 
structed by using different combinations of 
the reagent concentrations (conj-5 and RBP 
beads). As shown in Fig. 5, each curve has 
different dose-response behavior (i.e., detec- 
tion limits, effective detection range, and 
steepness) and exhibits negligible nonspecific 
adsorption of the conjugates (zero bound en- 
zyme activity at high riboflavin concentra- 
tions). Decreasing the conjugate concentra- 
tion with increasing the binder concentration 
results in a steeper curve with a higher detec- 
tion limit. Our theoretical treatment indi- 
cates that such a change in the steepness 
cannot occur in the case of K* > K(34). This 
implies that even the highly substituted con- 
jugate (a degree of conjugation of 20.7) has 
less affinity for immobilized RBP than ribo- 
flavin (K N 7.8 X 10’ M-l) (19). Assuming 
Ktit = nK*, each ligand molecule attached to 
the enzyme label (G6PDH) can be estimated 
to have an association constant lower than 
For the real sample measurements, any of 
the calibration curves in Fig. 5 can be uti- 
lized. As little as 0.3 rig/ml (8.6 X 10-i’ M) 
and 2.2 rig/ml (5.9 X lo-’ M) ( or 0.7 and 4.7 
pmol per assay tube) can be detected with 
curves A and C, respectively (detection limits 
determined at dose yielding 90% of zero dose 
signal). Since the normal levels of serum and 
urine riboflavin for humans are approxi- 
mately 20-240 (35,36) and 10-3000 rig/ml 
(2 1,37), respectively, both curves could, in 
principle, be used for these physiological 
samples. 
To demonstrate the analytical utility of the 
proposed assay, preliminary studies involv- 
ing the determination of riboflavin in urine, 
commercial multivitamin preparations, and 
infant formula were undertaken. The assay 
requires only a simple dilution of the original 
sample. A new calibration curve (Fig. 6), 
using standards falling on only the steep por- 




log (riboflavin), in standards, M 
-6 
FIG. 5. Effect of various reagent concentrations (conj-5 and RBP beads) on the shape of the riboflavin 
dose-response curves. The conjugate concentration and the absolute amount of RBP beads used for each 
curve were as follows: (A) 7.25 X 10m9~, 2.0 ~1; (B) 3.63 X 10m9~, 3.5 pl; (C) 1.81 X 10m9~, 8.0 pl. 
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0.1 I, I I I 
1xKi* 2X10-a 4X16’ 6X10-’ 6X10-’ 
lriboflavinl , in standards, M 
FIG. 6. Typical calibration curve used for the assay of riboflavin in real samples (prepared by using 
standards falling on only the steep portion of dose-response curve A in Fig. 5). 
(curve A in Fig. 5), was prepared for this 
purpose. The results from 22 random urine 
samples (average value = 1185 rig/ml; range 
= 188-3764 rig/ml) coincided well with the 
ranges reported by others (2 l-23) for normal 
urine. High selectivity over a wide range of 
other vitamins (vitamin Br, vitamin Be, vi- 
tamin B12, folic acid, pantothenic acid, nia- 
cin, etc.) was demonstrated by the results 
from the multivitamin preparations (B 
Complex 50 (Wm. T. Thompson Co.), found 
= 44.6 + 1.3 mg/capsule (n = 3), claimed 
= 50 mg/capsule; Hi-B Complex (Schiff Bio- 
Food Products), found = 5.7 f 0.5 mg/cap- 
sule (n = 3), claimed = 6 mg/capsule). The 
values obtained from the infant formula 
(Enfamil (Mead Johnson & Co.), found 
= 353 f 25 pg/5 fl. oz (n = 3) claimed = 156 
pg/5 fl. oz; ProSobee (Mead Johnson & 
Co.,), found = 318 + 7.5 pg/5 fl. oz (n = 3), 
claimed = 94 pg/5 fl. oz) far exceeded the 
labeled values; however, according to the 
manufacturer, the difference between mini- 
mum (labeled) and maximum riboflavin 
content of the products could be as high as 
500% to ensure proper shelf life. 
spiking the samples with three different 
amounts of the riboflavin standard. As can 
be seen in Table 2, the amounts of riboflavin 
used to spike the samples were recovered 
with satisfactory accuracy even from such a 
complex sample as infant formula. 
The assay system was further character- 
ized by evaluating its selectivity over several 
structurally related flavin analogs; lumifla- 









Urineb 0.39 f  0.03 0.398 98.0 
0.75 f  0.05 0.796 94.2 
1.07 + 0.06 1.194 89.6 
ProSob& 2.14 f  0.13 2.215 96.6 
4.43 + 0.59 4.430 100.0 
6.73 + 0.69 6.644 101.3 
Recovery studies were also performed for 
the urine and the infant formula samnles bv 
a Reported as a mean of three determinations f  stan- 
dard deviation. 
b Initial concentration determined to be 0.23 &ml. 
. -~, ’ Initial concentration determined to be 3.74 rg/ml. 
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species may be present in biological samples 
and could interfere with the riboflavin assay. 
The percentage cross-reactivity (defined as 
100 X [analyte]/[interferent] in which each 
concentration produces 50% of the maxi- 
mum response) was calculated for each ana- 
log and is provided in Table 3 along with the 
corresponding association constant toward 
RBP determined by fluorescence titration 
( 19). As can be seen, the values correlate well 
except for FMN, which is higher than ex- 
pected based on the known association con- 
stant. However, it should be mentioned that 
the proposed assay system utilizes a cova- 
lently immobilized RBP which may differ 
somewhat from soluble RBP in its associa- 
tion characteristics toward other flavins. The 
degree of cross-reactivity of RBP with other 
flavin analogs including FMN, as observed 
in this study, may explain, in part, previous 
observations in which RBP-based assays fre- 
quently measure a greater riboflavin concen- 
tration than does the L. case&based micro- 
biological assay (2 1,22). Such increases 
would also be expected in the proposed 
method if these analogs were present at levels 
2 riboflavin. 
In summary, a new heterogeneous, noniso- 
topic assay method for riboflavin has been 
described. The method is simple, sensitive, 
and selective for riboflavin over other vita- 
TABLE 3 
GAVIN CROSS-REACTIVITY OF NEW ENZYME- 
LINKED RIBOFLAVIN ASSAY 
Association 
Percentage constant* 
Flavin cross-reactivity (M-l) 
Riboflavin 100 7.8 x 10’ 
Lumiflavin 7.3 2.1 x 10’ 
Lumichrome 1.3 1.1 x 10’ 
FMN 9.3 7.3 x lo5 
FAD 0.4 <7.0 x lo4 
a Determined by dividing the concentration of ribofla- 
vin at 50% maximum bound label by the concentration 
of analog that yields 50% maximum bound label. 
* Determined by fluorescence titration (from Ref. 
(19)). 
mins. Given the promising preliminary data 
obtained for real sample measurements and 
the subsequent recovery studies, the proposed 
method may offer an attractive alternative to 
existing techniques for the detection of ribo- 
flavin in a variety of samples. At the same 
time, we have once again demonstrated that 
natural binding proteins can be used effec- 
tively in conjunction with appropriate en- 
zyme-ligand conjugates to devise useful com- 
petitive binding assays. This approach is 
highly recommended in cases where antibody 
production toward the analyte is difficult 
(e.g., toward endogenous vitamins) or when 
proper immune response yields antibodies 
which exhibit strong recognition of the bridge 
group in the required enzyme-analyte conju- 
gates (increased K* values) (34). 
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